Lambrolizumab Typical Properties

Lambrolizumab Usage

Pembrolizumab is a humanized antibody used in cancer immunotherapy. It is an IgG4 isotype antibody that blocks a protective mechanism of cancer cells, and allows the immune system to destroy those cancer cells. It targets the programmed cell death 1 (PD-1) receptor of lymphocytes. The FDA initially approved it to treat metastatic melanoma.

Application  Pharma grade or research purpose

Shelf life 2 years

Lambrolizumab Supply Ability

1000 Kilogram/Kilograms per Month

Lambrolizumab Storage

1G 10G 100G/BAG

Lambrolizumab Indications

1) Disease progression after unresectable or metastatic melanoma and primima, such as BRAFV600 mutation positive.
2) The FDA-approved test confirms metastatic NSCLC and disease progression after or with platinum-containing chemotherapy. Before receiving KEYTRUDA, use FDA-approved treatment for these aberrant patients with EGFR or ALK genomic tumor aberrations.

Lambrolizumab Dosage

The recommended dose of pembrolizumab is: once every three weeks, 200 mg each time, intravenous drip in 30 minutes. Until the disease progresses or unacceptable toxicity occurs, if the disease does not progress, use it up to 24 months. When used in combination with other chemotherapy drugs, pembrolizumab must be given before chemotherapy.